Latest News and Press Releases

BLOOMFIELD, Conn., Sept. 13, 2022 (GLOBE NEWSWIRE) -- LiquidPiston, Inc., the leading innovator of efficient engine technology and hybrid power systems, today announced a $1.7 million Phase II award...

First patient dosed with HB-200 and pembrolizumab combination for treatment of 1st-line advanced/metastatic head and neck cancer in Phase 2 arm of ongoing Phase 1/2 trial Fast Track Designation...

DORAL, FL, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), an innovative biotech company focused in nutraceutical and pharmaceutical fields, and...

TORONTO, May 08, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating...

Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...

 PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no...

Sellbyville, Delaware, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Global Pharmacovigilance Market will surpass USD 8.0 billion by 2024; according to a new research report by Global Market Insights, Inc....

VANCOUVER, British Columbia, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to announce that it will be...

Sellbyville, Delaware, March 19, 2018 (GLOBE NEWSWIRE) -- Global Pharmacovigilance Market is set to exceed USD 8 billion by 2024; according to a new research report by Global Market Insights....

Doral, Nov. 14, 2017 (GLOBE NEWSWIRE) --  Earth Science Tech, Inc. (OTC PINK: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of industrial hemp...